-
公开(公告)号：US20170128394A1
公开(公告)日：2017-05-11
申请号：US14971153
申请日：2015-12-16
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Thomas Efferth , Su-Wei Xu , Sami Hamdoun , Liang Liu
IPC: A61K31/19 , A61K31/553 , A61K31/704 , A61K31/7048 , A61K31/337 , A61K33/24
CPC classification number: A61K31/19 , A61K31/337 , A61K31/553 , A61K31/704 , A61K31/7048 , A61K33/24 , A61K2300/00
Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.
-
52.发明授权Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof 有权生物碱组，用于治疗癌症的新型自噬增强剂及其神经变性病症公开(公告)号：US09561220B2
公开(公告)日：2017-02-07
申请号：US14985414
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4745 , A61K31/4725 , A61K31/4748
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
Abstract translation: 本发明公开了一种治疗癌症的方法，该方法包括给予有效量的生物碱，其中生物碱为留丝氨酸，依沙星碱，屈酸，去甲肾上腺素，栀子或沙利度胺，并从中药中分离出来。 还公开了使用生物碱治疗神经变性疾病。
-
Patent Agency Ranking
53.发明授权Methods for novel drug discovery, treatment and selective targeting for gefitinib-resistant non-small-cell lung cancer harboring T790M mutation 有权新型药物发现，治疗和选择性靶向吉非替尼耐药性非小细胞肺癌携带T790M突变的方法公开(公告)号：US09439898B2
公开(公告)日：2016-09-13
申请号：US14296477
申请日：2014-06-05
Applicant: Macau University of Science and Technology
Inventor： Elaine Lai-Han Leung , Liang Liu , Xing-Xing Fan
IPC: C12Q1/68 , A61K31/4741 , A61K33/40 , G01N33/50
CPC classification number: A61K31/4741 , A61K33/40 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156 , G01N33/5011 , G01N2333/90209 , G01N2333/91205 , A61K2300/00
Abstract: The present invention relates to methods for novel drug discovery, treatment and selective targeting for Gefitinib-resistant non-small-cell lung cancer (NSCLC) harboring an additional mutation, in particular, to the discovery of a drug candidate or agent identified by the presently claimed method for use in treating and selective targeting Gefitinib-resistant NSCLC harboring T790M mutation.
Abstract translation: 本发明涉及具有另外突变的吉非替尼耐药性非小细胞肺癌（NSCLC）的新药物发现，治疗和选择性靶向的方法，特别涉及目前鉴定的候选药物或药物的发现 所述方法用于治疗和选择性靶向具有T790M突变的吉非替尼耐药性NSCLC。
-
公开(公告)号：US20160106734A1
公开(公告)日：2016-04-21
申请号：US14985420
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4748 , A61K31/4725
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
-
公开(公告)号：US20160106729A1
公开(公告)日：2016-04-21
申请号：US14985408
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4725
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
-
56.发明授权Ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury 有权人参皂甙衍生物及其在保护缺血/再灌注损伤中的应用公开(公告)号：US09273088B2
公开(公告)日：2016-03-01
申请号：US14055883
申请日：2013-10-17
Applicant: Macau University of Science and Technology
Inventor： Jingrong Wang , Pei Luo , Hua Zhou , Wai In Chan , Liang Liu , Zhihong Jiang
IPC: A61K31/704 , C07J17/00
CPC classification number: C07J17/005 , A61K31/704
Abstract: The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.
Abstract translation: 本发明提供新型人参皂苷衍生物化合物及其在防止缺血/再灌注损伤中的应用。
-
公开(公告)号：US09005677B2
公开(公告)日：2015-04-14
申请号：US14231671
申请日：2014-03-31
Applicant: Macau University of Science and Technology
Inventor： Yuen Kwan Law , An Guo Wu , Kam Wai Wong , Liang Liu
CPC classification number: A61K36/69 , A61K31/704
Abstract: Use and application of Onjisaponin B derived and isolated from Radix Polygalae as novel autophagy enhancer are provided. A method of preventing, treating and/or delaying the onset of neurodegenerative diseases comprising administering an effective amount of Onjisaponin B is also provided.
Abstract translation: 本发明提供了从根部提取和分离的Onjisaponin B作为新的自噬增强剂的应用和应用。 还提供了预防，治疗和/或延缓神经变性疾病发作的方法，包括给予有效量的Onjisaponin B.
-
-
-
-
-
-
Search Results
57
records
(took 0.025 seconds)
